Filed 23 Jul 2026
- Raw material cost pressures from West Asia crisis persist; partial pass-through achieved; operating leverage expected but limited.
- Capex of βΉ55-60 Cr in FY27 focused on de-bottlenecking (βΉ40 Cr) and maintenance (βΉ10-15 Cr); similar levels planned for FY28-29.
- EBITDA margin for base business targeted at ~25% Β±1% in FY27.
- Net debt reduction target to sub-βΉ450 Cr by March 2027, improving net debt/EBITDA to ~1.7x.
- Ibuprofen business EBITDA margin negative ~12%, expected to sustain losses of βΉ10-15 Cr per quarter.
- Focus on brownfield de-bottlenecking to increase capacity by 20-30% on high-margin products with quick payback.